Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells

• US 7,311,905 B2
• Filed: 02/13/2003
• Issued: 12/25/2007
• Est. Priority Date: 02/13/2002
• Status: Expired due to Term

• Current Assignee: Celularity, Inc.
• Original Assignee: Anthrogenesis Corporation (Bristol-Myers Squibb Company)
• Inventors: Hariri, Robert J.
• Primary Examiner(s): LI, QIAN JANICE
• Application Number:
  US10/366,671
• Publication Number:
  US 20030180269A1
• Time in Patent Office: 1,776 Days
• Field of Search: None
• US Class Current: 424/93.1
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 35/50 Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• CPC Class Codes: A61K 35/51 Umbilical cord; Umbilical cord blood; Umbilical stem cells
• CPC Class Codes: A61K 35/545 Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61M 1/02 Blood transfusion apparatus blood infusion by syringes A61M5/14
• CPC Class Codes: A61M 2202/0462 Placental blood, umbilical cord blood
• CPC Class Codes: A61M 2210/1458 Placenta
• CPC Class Codes: A61M 2210/1466 Umbilical cord
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12N 2500/90 : Serum-free medium, which may still contain naturally-sourced components
• CPC Class Codes: C12N 2509/00 : Methods for the dissociation of cells, e.g. specific use of enzymes
• CPC Class Codes: C12N 2533/90 : Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
• CPC Class Codes: C12N 5/0068 : General culture methods using substrates for specific animal cell type C12N5/06
• CPC Class Codes: C12N 5/0605 : Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
• CPC Class Codes: C12N 5/0607 : Non-embryonic pluripotent stem cells, e.g. MASC induced pluripotent stem cells C12N5/0696

Abstract

The present invention provides compositions and methods of using embryonic-like stem cells that originate from a post-partum placenta with conventional cord blood compositions or other stem or progenitor cells. The embryonic-like stem cells can be used alone or in a mixture with other stem cell populations. In accordance with the present invention, the embryonic-like stem cells may be mixed with other stem cell populations, including but not limited to, umbilical cord blood, fetal and neonatal hematopoietic stem cells and progenitor cells, human stem cells and progenitor cells derived from bone marrow. The embryonic-like stem cells and the mixed populations of embryonic-like stem cells and stem cells have a multitude of uses and applications, including but not limited to, therapeutic uses for transplantation and treatment and prevention of disease, and diagnostic and research uses.

Claims

1. A composition comprising human stem or progenitor cells and isolated human placental stem cells that are SH2⁺, SH3⁺, SH4⁺ and OCT-4⁺, wherein said placental stem cells are obtained from a placenta that has been drained of cord blood and flushed to remove residual blood.

5. The composition of any of claim 1, 2, 3 or 4 that is contained in a container.

6. The composition of claim 5 wherein the container is sealed, air tight, and sterile.

7. The composition of claim 1 or claim 3 wherein the stem or progenitor cells are from umbilical cord blood or placental blood, fetal or neonatal hematopoietic stem or progenitor cells, adult cells or bone marrow stem or progenitor cells.

8. The composition of claim 7 wherein the stem or progenitor cells are fetal or neonatal hematopoietic stem or progenitor cells.

9. The composition of claim 8 wherein a plurality of the hematopoietic stem or progenitor cells are CD34⁺ and CD38⁻

.

12. The composition of claim 1 or 2 wherein the placental stem cells exhibit at least one of the following cell surface markers:

CD10, CD29, CD44, CD54, or CD90, or lack at least one of the following cell surface markers;

CD34, CD45, SSEA3, or SSEA4.

13. A kit comprising a composition of claim 1 or 3 wherein said stem or progenitor cells are in a first container and said placental stem cells are in a second container.

2. A composition comprising human umbilical cord blood cells and isolated human placental stem cells that are SH2⁺, SH3⁺, SH4⁺ and OCT-4⁺, wherein said placental stem cells are obtained from a placenta that has been drained of cord blood and flushed to remove residual blood.

10. The composition of claim 2 or claim 4 wherein a plurality of the umbilical cord blood stem cells are CD34⁺ and CD38⁺.

11. The composition of claim 2 or claim 4 wherein a plurality of the umbilical cord blood stem cells are CD34⁺ and CD38⁺.

16. A kit comprising a composition of claim 2 or claim 4 wherein said umbilical cord blood cells are in a first container and said placental stem cells are in a second container.

3. A composition comprising human stem or progenitor cells and isolated human placental stem cells that are SH2⁺, SH3⁺, SH4⁺, SSEA3⁻

and SSEA4⁻

, wherein said placental stem cells are obtained from a placenta that has been drained of cord blood and flushed to remove residual blood.

15. The composition of claim 3 or 4 wherein the placental stem cells exhibit at least one of the following cell surface markers:

CD10, CD29, CD44, CD54, CD90, or OCT-4, or lack at least one of the following cell surface markers;

CD34 or CD45.

4. A composition comprising human umbilical cord blood cells and isolated human placental stem cells that are SH2⁺, SH3⁺, SH4⁺, SSEA3⁻

and SSEA4⁻

, wherein said placental stem cells are obtained from a placenta that has been drained of cord blood and flushed to remove residual blood.

14. A composition which comprises human stem or progenitor cells from umbilical cord blood supplemented with a plurality of isolated human placental stem cells that are SH2⁺, SH3⁺, SH4⁺ and OCT-4⁺, wherein said placental stem cells are obtained from a placenta that has been drained of cord blood and flushed to remove residual blood, and wherein the ratio of placental stem cells to said stem or progenitor cells is at least 1:

1 in numbers.

17. A composition which comprises a number of human stem or progenitor cells from umbilical cord blood supplemented with a number of isolated human placental stem cells that are SH2⁺, SH3⁺, SH4⁺, SSEA3⁻

and SSEA4³¹ , wherein said placental stem cells are obtained from a placenta that has been drained of cord blood and flushed to remove residual blood, and wherein the ratio of the number of placental stem cells to the number of said stem or progenitor cells is at least 1;

1.